Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20109153 | 0.90 | MEN1 (0.33) | MAPTSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL20109348 | 0.86 | GFER (0.42) | GFERMAPTACHELMNAGAA | |
| SCHEMBL20109217 | 0.84 | GFER (0.41) | GFERMAPTACHECCR1RXFP1 | |
| SCHEMBL20109254 | 0.84 | GFER (0.41) | GFERMAPTACHECCR1RXFP1 | |
| SCHEMBL17596429 | 0.81 | ALDH1A1 (0.43) | MAPTSMN1; SMN2GAAALDH1A1KMT2A | |
| SCHEMBL20109140 | 0.77 | CHRNA7 (0.36) | MAPTLMNAALDH1A1TSHRDRD2 | |
| SCHEMBL17596721 | 0.76 | MEN1 (0.42) | MAPTLMNASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL20109231 | 0.73 | ADRB1 (0.33) | MAPTLMNAALDH1A1KMT2A | |
| SCHEMBL23357432 | 0.72 | L3MBTL1 (0.46) | MAPTLMNASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL20113635 | 0.71 | MAPT (0.44) | MAPTSMN1; SMN2GAAALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118770-A1 | N-Heterocyclic Phosphines | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118770-A1 | N-Heterocyclic Phosphines | NANP, PPIP5K2, PHPT1 | GFER 2292/4885MAPT 4371/4885ACHE 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.